KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Esperion Therapeutics (ESPR) Non Operating Income: 2011-2024

Historic Non Operating Income for Esperion Therapeutics (ESPR) over the last 14 years, with Dec 2024 value amounting to $8.0 million.

  • Esperion Therapeutics' Non Operating Income fell 57.26% to $677,000 in Q3 2025 from the same period last year, while for Sep 2025 it was $3.6 million, marking a year-over-year decrease of 54.12%. This contributed to the annual value of $8.0 million for FY2024, which is 51.62% up from last year.
  • Per Esperion Therapeutics' latest filing, its Non Operating Income stood at $8.0 million for FY2024, which was up 51.62% from $5.3 million recorded in FY2023.
  • Esperion Therapeutics' Non Operating Income's 5-year high stood at $8.0 million during FY2024, with a 5-year trough of $515,000 in FY2020.
  • Over the past 3 years, Esperion Therapeutics' median Non Operating Income value was $5.3 million (recorded in 2023), while the average stood at $5.3 million.
  • In the last 5 years, Esperion Therapeutics' Non Operating Income tumbled by 87.30% in 2020 and then surged by 671.84% in 2021.
  • Yearly analysis of 5 years shows Esperion Therapeutics' Non Operating Income stood at $515,000 in 2020, then soared by 671.84% to $4.0 million in 2021, then plummeted by 33.28% to $2.7 million in 2022, then soared by 99.51% to $5.3 million in 2023, then soared by 51.62% to $8.0 million in 2024.